Exosomes, Microvesicles and Other Extracellular Vesicles
Scientific Organizers: Clotilde Thery, Andrew Hill and Susmita Sahoo
Date: February 20 - 23, 2022
Location: Eldorado Hotel & Spa, Santa Fe, NM, USA
For important information on the coronavirus, please click here
Extracellular vesicles (EVs), including exosomes, microvesicles and others are membranous nanovesicles, contain bioactive molecules such as lipids, proteins, RNA and metabolites derived from the cell of their origin. EVs carry these important cargo molecules throughout the body, signaling to distant tissues and orchestrating systemic responses. The profile of cargo they carry provides a cell-specific signature, which can reveal important insights about the cell of origin, and pathophysiological mechanisms. As such, there is growing excitement about their potential use as disease biomarkers, and/or therapeutic entities. The goal of this meeting is to disseminate the latest discoveries regarding both basic biology and clinical utility of EVs. In particular, the program will explore the role of EVs in human disease pathogenesis, novel therapeutic approaches with EVs, and biomarker developments. In addition to scientific insights, the meeting will cover new methodologies, tools and technologies for studying EVs, to enable further advancements in characterization of EV processes and facilitate translational impact into diagnostic and therapeutic applications. By integrating research in basic science with the clinical perspectives, this meeting will foster cross-disciplinary discussions and collaborations to drive the field forward towards medical impacts. In addition, the program format features panel discussions and workshops to spur insightful discussions and encourage interactions between young investigators and distinguished international experts for training, mentorship and networking opportunities.
Scholarship Deadline: November 9 2021 details
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies